{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T07:38:40Z","timestamp":1762846720244,"version":"build-2065373602"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Children with acute liver failure (ALF) often experience hyperammonaemia, fluid overload, metabolic derangements, and multi-organ failure. Continuous renal replacement therapy (CRRT) is commonly used for renal and non-renal indications, particularly in those with hyperammonaemia and hepatic encephalopathy. However, the non-selective nature of CRRT can result in the clearance of beneficial metabolites and liver-related biomarkers, which are important for monitoring disease progression or improvement. Therefore, understanding the kinetic principles governing molecular clearance during CRRT is crucial for accurate interpretation of liver biochemistry to inform clinical decision-making. By considering the kinetic properties of hepatic markers, including bilirubin, bile acids, liver enzymes, metabolites, waste products, inflammatory markers, albumin, and coagulation proteins, we describe the impact of CRRT on the plasma levels of these markers. In addition, we discuss various CRRT attributes, and the removal of these markers is also discussed. Metabolites and waste products, including ammonia, lactate, and urea, are the most useful markers to inform CRRT responsiveness, owing to their small molecular size, low degree of protein binding, and small volume of distribution; whereas bilirubin, bile acids, coagulation factors, and albumin remain true indicators of hepatic function and clinical condition. It should be noted that the overall plasma levels of any molecules reflect the balance between production and clearance, even for molecules with a high degree of CRRT removal. Awareness of these properties helps clinicians differentiate dialytic response versus genuine hepatic recovery or deterioration, guiding a more rational interpretation of clinical progression in ALF with liver transplant\/spontaneous native recovery or mortality as the outcomes.<\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusion<\/jats:italic>\n                    : Understanding the kinetic behaviour of liver-related markers during CRRT is essential to distinguish\u00a0between dialytic clearance and true changes in hepatic function. This knowledge enables more accurate clinical interpretation,\u00a0guiding decision-making in children with acute liver failure and optimizing management strategies toward recovery or timely\u00a0transplantation.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:table-wrap>\n                      <jats:table>\n                        <jats:tbody>\n                          <jats:tr>\n                            <jats:td colspan=\"2\">\n                              <jats:bold>What is Known:<\/jats:bold>\n                              \u2022\u00a0\n                              <jats:italic>Children with acute liver failure often require CRRT for non-renal causes, including metabolic derangements, hyperammonemia,\u00a0and multi-organ support.<\/jats:italic>\n                              \u2022\u00a0\n                              <jats:italic>CRRT non-selectively clears both toxic metabolites and liver-related biomarkers, complicating the interpretation of hepatic function.<\/jats:italic>\n                              <jats:bold>What is New:<\/jats:bold>\n                              \u2022\u00a0\n                              <jats:italic>Accounting for the kinetic properties of liver markers during CRRT allows clinicians to distinguish dialytic clearance from true hepatic\u00a0recovery or deterioration.<\/jats:italic>\n                              \u2022\u00a0\n                              <jats:italic>Small molecules (ammonia, lactate, urea) might reflect CRRT responsiveness, whereas bilirubin, bile acids, albumin, and\u00a0coagulation factors indicate liver function and clinical status.<\/jats:italic>\n                            <\/jats:td>\n                          <\/jats:tr>\n                        <\/jats:tbody>\n                      <\/jats:table>\n                    <\/jats:table-wrap>\n                  <\/jats:p>","DOI":"10.1007\/s00431-025-06512-y","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:41:51Z","timestamp":1760150511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interpreting liver function markers in children on continuous renal replacement therapy for acute liver failure"],"prefix":"10.1007","volume":"184","author":[{"given":"Wun Fung","family":"Hui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akash","family":"Deep","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"issue":"7","key":"6512_CR1","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.14309\/ajg.0000000000002340","volume":"118","author":"A Shingina","year":"2023","unstructured":"Shingina A, Mukhtar N, Wakim-Fleming J, Alqahtani S, Wong RJ, Limketkai BN, Larson AM, Grant L (2023) Acute liver failure guidelines. Am J Gastroenterol 118(7):1128\u20131153. https:\/\/doi.org\/10.14309\/ajg.0000000000002340","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"6512_CR2","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jhep.2016.12.003","volume":"66","author":"J Wendon","year":"2017","unstructured":"Wendon J, Cordoba J, Dhawan A, Larsen FS, Manns M, Samuel D, Simpson KJ, Yaron I, Bernardi M (2017) EASL clinical practical guidelines on the management of acute (fulminant) liver failure. J Hepatol 66(5):1047\u20131081. https:\/\/doi.org\/10.1016\/j.jhep.2016.12.003","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"6512_CR3","doi-asserted-by":"publisher","first-page":"S104","DOI":"10.1016\/j.jceh.2014.11.005","volume":"5","author":"ASK Shalimar","year":"2015","unstructured":"Shalimar ASK (2015) Management in acute liver failure. J Clin Exp Hepatol 5(Suppl 1):S104-115. https:\/\/doi.org\/10.1016\/j.jceh.2014.11.005","journal-title":"J Clin Exp Hepatol"},{"issue":"1","key":"6512_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s00134-018-5213-x","volume":"45","author":"G Hernandez","year":"2019","unstructured":"Hernandez G, Bellomo R, Bakker J (2019) The ten pitfalls of lactate clearance in sepsis. Intensive Care Med 45(1):82\u201385. https:\/\/doi.org\/10.1007\/s00134-018-5213-x","journal-title":"Intensive Care Med"},{"issue":"8","key":"6512_CR5","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1016\/j.ekir.2021.05.004","volume":"6","author":"RH Bouajram","year":"2021","unstructured":"Bouajram RH, Awdishu L (2021) A clinician\u2019s guide to dosing analgesics, anticonvulsants, and psychotropic medications in continuous renal replacement therapy. Kidney Int Rep 6(8):2033\u20132048. https:\/\/doi.org\/10.1016\/j.ekir.2021.05.004","journal-title":"Kidney Int Rep"},{"issue":"3","key":"6512_CR6","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.chest.2018.09.004","volume":"155","author":"S Tandukar","year":"2019","unstructured":"Tandukar S, Palevsky PM (2019) Continuous renal replacement therapy: who, when, why, and how. Chest 155(3):626\u2013638. https:\/\/doi.org\/10.1016\/j.chest.2018.09.004","journal-title":"Chest"},{"key":"6512_CR7","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1046\/j.1523-1755.56.s.72.2.x","volume":"72","author":"J B\u00f6hler","year":"1999","unstructured":"B\u00f6hler J, Donauer J, Keller F (1999) Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. Kidney Int Suppl 72:S24\u2013S28","journal-title":"Kidney Int Suppl"},{"issue":"10","key":"6512_CR8","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1097\/CCM.0000000000001826","volume":"44","author":"A Deep","year":"2016","unstructured":"Deep A, Stewart CE, Dhawan A, Douiri A (2016) Effect of continuous renal replacement therapy on outcome in pediatric acute liver failure. Crit Care Med 44(10):1910\u20131919. https:\/\/doi.org\/10.1097\/CCM.0000000000001826","journal-title":"Crit Care Med"},{"key":"6512_CR9","doi-asserted-by":"publisher","unstructured":"Bottari G, Buccione E, Bayrakci B, Briassoulis G, Carter MJ, Demirkol D, Ilia S, Morin L, Reiter K, Santiago MJ, Schlapbach LJ, Slocker-Barrio M, Tissieres P, Zaoral T, Bianzina S, Deep (2025) Extracorporeal blood purification in European pediatric intensive care units: a consensus statement. JAMA Netw Open 8(2):e2457657. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.57657.","DOI":"10.1001\/jamanetworkopen.2024.57657"},{"issue":"4\u20135","key":"6512_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1159\/000512100","volume":"50","author":"T Naorungroj","year":"2021","unstructured":"Naorungroj T, Yanase F, Eastwood GM, Baldwin I, Bellomo R (2021) Extracorporeal ammonia alearance for hyperammonemia in critically ill patients: a scoping review. Blood Purif 50(4\u20135):453\u2013461. https:\/\/doi.org\/10.1159\/000512100","journal-title":"Blood Purif"},{"issue":"1","key":"6512_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/00003246-199701000-00013","volume":"25","author":"J Levraut","year":"1997","unstructured":"Levraut J, Ciebiera JP, Jambou P, Ichai C, Labib Y, Grimaud D (1997) Effect of continuous venovenous hemofiltration with dialysis on lactate clearance in critically ill patients. Crit Care Med 25(1):58\u201362. https:\/\/doi.org\/10.1097\/00003246-199701000-00013","journal-title":"Crit Care Med"},{"issue":"3","key":"6512_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/00024382-200115030-00002","volume":"15","author":"M Meisner","year":"2001","unstructured":"Meisner M, H\u00fcttemann E, Lohs T, Kasakov L, Reinhart K (2001) Plasma concentrations and clearance of procalcitonin during continuous veno-venous hemofiltration in septic patients. Shock 15(3):171\u2013175. https:\/\/doi.org\/10.1097\/00024382-200115030-00002","journal-title":"Shock"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06512-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-025-06512-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06512-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T07:35:24Z","timestamp":1762846524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-025-06512-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":12,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["6512"],"URL":"https:\/\/doi.org\/10.1007\/s00431-025-06512-y","relation":{},"ISSN":["1432-1076"],"issn-type":[{"type":"electronic","value":"1432-1076"}],"subject":[],"published":{"date-parts":[[2025,10,11]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The manuscript involves no collection of patient data, and no ethics approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"675"}}